ArticleBeilstein journal of nanotechnology2025
A nanocarrier containing carboxylic and histamine groups with dual action: acetylcholine hydrolysis and antidote atropine delivery.
Article in Beilstein journal of nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disruption of cholinesterases and, as a consequence, increased levels of acetylcholine lead to serious disturbances in the functioning of the nervous system, including death. The need for rapid administration of an antidote to restore esterase activity is critical, but practical implementation of this is often difficult. One promising solution may be the development of antidote delivery systems that will release the drug only when acetylcholine levels are elevated. This approach will ensure timely delivery of the antidote and minimize side effects associated with uncontrolled drug release. Here, we describe the creation of a new smart system that serves as a carrier for delivering an antidote (i.e., atropine) and functions as a synthetic esterase to hydrolyze acetylcholine. The nanocarrier was synthesized through microemulsion polycondensation of phenylboronic acid with resorcinarenes containing hydroxy, imidazole, and carboxylic groups on the upper rim. The nanocarrier breaks down acetylcholine into choline and acetic acid. The latter acts on the boronate bonds, dissociating them. This leads to the destruction of the nanocarrier and the release of the antidote. The paper covers the creation of the nanocarrier, its physicochemical and biological properties, encapsulation of the antidote, acetylcholine hydrolysis, and antidote release.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.